You just read:

Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers

News provided by

Viracta Therapeutics, Inc.

Apr 16, 2019, 08:00 ET